Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer
(Thomson Reuters ONE) -
Affimed Therapeutics AG /
Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Heidelberg, Germany, November 12, 2013: Affimed Therapeutics AG, the TandAb
antibody company, announced today the appointment of Dr. Jens-Peter Marschner as
Chief Medical Officer, effective October 1(st), 2013.
Dr. Marschner recently joined Affimed from Merck KGaA. He has 18 years of
professional experience in clinical development with a focus on biological
compounds. Working in several pharmaceutical companies, he has been responsible
for conducting clinical trials in all phases of development. Dr. Marschner led
the clinical development team of cetuximab (Erbitux), a monoclonal antibody to
treat colorectal cancer, which was successfully launched in 2004. During his
career he has also been responsible for the early and late stage development of
cancer immune therapies. As VP Global Medical Affairs at Merck KGaA Dr.
Marschner gained comprehensive experience in market-related medical and
scientific affairs, primarily in the field of oncology.
Dr. Adi Hoess, CEO of Affimed Therapeutics, commented: "I am delighted to
welcome Jens-Peter as a key member of the Executive Management Board. His expert
knowledge and experience in oncology drug development and management adds
significantly to our company and our future. Jens-Peter's expertise will ensure
that Affimed continues to build on its leadership in the development of
bispecific immunotherapies."
"Bi-specific antibodies will play a major role in the future treatment of
cancer. Affimed's TandAb® technology has the potential to provide major benefit
to patients affected by hematologic malignancies, which our lead compounds
target," said Dr. Jens-Peter Marschner, CMO of Affimed Therapeutics. "The
opportunity to help patients by developing these promising antibodies is a
strong motivator for my work and I am very excited to join the team."
Dr. Marschner initially trained and worked as a medical doctor. After finishing
the clinical work at a general hospital (internal medicine) he worked at the
University Hospital Frankfurt/Main where he became a board certified Clinical
Pharmacologist. He started his pharmaceutical career in 1995 at Boehringer
Mannheim, which is now part of Roche. After a shorter tenure at Bayer he joined
Merck KGaA in 1999. Along with his responsibility for the development of several
biological compounds he managed different global teams in Clinical Development
and Medical Affairs.
For further information please contact:
Affimed Therapeutics AG MC Services AG
Dr. Adi Hoess (CEO) Anne Hennecke
Tel.: + 49 6221 65307 0 Tel.: +49 89 210 228 18
Fax: + 49 6221 65307 77 Fax: +49 89 210 228 88
a.hoess(at)affimed.com anne.hennecke(at)mc-services.eu
About TandAbs and Affimed's immunotherapeutic product candidates
TandAbs®, which were invented and developed by Affimed scientists, are
tetravalent bispecific antibody formats that have two binding sites for each
antigen. They bind to target molecules on the surface of tumor cells and
specifically activate immune effector cells such as cytotoxic T cells or natural
killer (NK) cells in the presence of tumor cells. This simultaneous binding to
both cells leads to an effective lysis of the tumor cells. TandAbs® possess the
same avidity and affinity for each target as an IgG. Combined with their
bispecificity, this format represents a potent further development of
therapeutic monoclonal antibodies and, potentially, a superior alternative to
first generation antibody formats/scaffolds.
AFM11 and AFM13 are Affimed's lead product candidates. The TandAb® AFM11 is
specifically designed to treat CD19-positive malignancies. It targets CD19 on
malignant B cells and engages CD3 on T cells. AFM11 recently has been filed with
regulatory agencies for the initiation of phase 1 clinical trials. The
TandAb® AFM13 is specifically designed to treat CD30-positive malignancies. It
targets CD30 on malignant cells and CD16A on NK cells. AFM13 has shown an
attractive safety profile and demonstrated a clinical effect in a Phase 1 study
in relapsing/refractory Hodgkin lymphoma patients.
About Affimed Therapeutics AG
Affimed Therapeutics AG is a therapeutic antibody company developing unique
antibody therapeutics as novel treatments for life threatening diseases with
high unmet medical needs. The company has generated a growing pipeline of drug
candidates based on its proprietary TandAb® antibody platform. Affimed's product
candidates are developed for the treatment of CD19-positive (AFM11) and CD30-
positive tumors (AFM13). Further novel product candidates are in development to
treat solid tumors and autoimmune diseases. Affimed's proprietary and highly
productive TandAb® technology enables the company to generate unique
tetravalent, bispecific, fully human antibody formats that promise increased
therapeutic potential and superior profiles compared to monoclonal antibodies.
The private company Affimed, which employs 30 people in Heidelberg, is a spin-
off from the German Cancer Research Centre (DKFZ), Heidelberg.
Press release (PDF):
http://hugin.info/142251/R/1742263/585652.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Affimed Therapeutics AG via Thomson Reuters ONE
[HUG#1742263]
Unternehmensinformation / Kurzprofil:
Datum: 12.11.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 315184
Anzahl Zeichen: 6590
contact information:
Town:
Heidelberg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Affimed Therapeutics Appoints Dr. Jens-Peter Marschner as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Affimed Therapeutics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
